Nanoparticle/Engineered Bacteria Based Triple-Strategy Delivery System for Enhanced Hepatocellular Carcinoma Cancer Therapy
Meiyang Yang,Weijun Chen,Dhanu Gupta,Congjin Mei,Yang Yang,Bingke Zhao,Lipeng Qiu,Jinghua Chen
DOI: https://doi.org/10.2147/ijn.s453709
IF: 7.033
2024-04-30
International Journal of Nanomedicine
Abstract:Meiyang Yang, 1, 2, &ast Weijun Chen, 1, &ast Dhanu Gupta, 3 Congjin Mei, 1 Yang Yang, 1 Bingke Zhao, 1 Lipeng Qiu, 1 Jinghua Chen 1 1 School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, People's Republic of China; 2 School of Chemical and Material Engineering, Jiangnan University, Wuxi, People's Republic of China; 3 Department of Paediatrics, University of Oxford, Oxford, UK &astThese authors contributed equally to this work Correspondence: Lipeng Qiu; Jinghua Chen, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, 214122, People's Republic of China, Email ; Background: New treatment modalities for hepatocellular carcinoma (HCC) are desperately critically needed, given the lack of specificity, severe side effects, and drug resistance with single chemotherapy. Engineered bacteria can target and accumulate in tumor tissues, induce an immune response, and act as drug delivery vehicles. However, conventional bacterial therapy has limitations, such as drug loading capacity and difficult cargo release, resulting in inadequate therapeutic outcomes. Synthetic biotechnology can enhance the precision and efficacy of bacteria-based delivery systems. This enables the selective release of therapeutic payloads in vivo. Methods: In this study, we constructed a non-pathogenic Escherichia coli ( E. coli ) with a synchronized lysis circuit as both a drug/gene delivery vehicle and an in-situ (hepatitis B surface antigen) Ag (ASEc) producer. Polyethylene glycol (CHO-PEG 2000 -CHO)-poly(ethyleneimine) (PEI 25k )-citraconic anhydride (CA)-doxorubicin (DOX) nanoparticles loaded with plasmid encoded human sulfatase 1 (hsulf-1) enzyme (PNPs) were anchored on the surface of ASEc (ASEc@PNPs). The composites were synthesized and characterized. The in vitro and in vivo anti-tumor effect of ASEc@PNPs was tested in HepG2 cell lines and a mouse subcutaneous tumor model. Results: The results demonstrated that upon intravenous injection into tumor-bearing mice, ASEc can actively target and colonise tumor sites. The lytic genes to achieve blast and concentrated release of Ag significantly increased cytokine secretion and the intratumoral infiltration of CD4/CD8 + T cells, initiated a specific immune response. Simultaneously, the PNPs system releases hsulf-1 and DOX into the tumor cell resulting in rapid tumor regression and metastasis prevention. Conclusion: The novel drug delivery system significantly suppressed HCC in vivo with reduced side effects, indicating a potential strategy for clinical HCC therapy. Keywords: hepatocellular carcinoma, engineered bacteria, chemotherapy, immunotherapy, anti-angiogenesis Graphical Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths globally. 1,2 The incidence and mortality rate of this disease have witnessed a rapid surge, primarily attributed to factors such as chronic hepatitis B and C virus infections, aflatoxin exposure, smoking, obesity, and diabetes. 3,4 Unfortunately, most HCC cases are diagnosed at an advanced stage, limiting treatment options and a poor 5-year survival rate (<15%). 5 Current clinical treatments for advanced HCC include liver transplantation, surgical resection, radiofrequency ablation, transarterial chemoembolization, and multi-kinase inhibitors. 6–8 Recently, immunotherapies, such as those targeting PD-1/PD-L1, have been clinically approved for HCC. 9–11 While liver transplantation is considered the best treatment for HCC, it remains infrequent due to limited donor availability, high rate of tumor recurrence and metastasis post-surgery. 5,12 Additionally, some patients face challenges in tumor resection, and for those with severe cirrhosis, resection can compromise normal liver functions. Radiofrequency ablation is a local treatment option for small HCCs ranging from 3 to 7 cm in diameter, but complete ablation of larger HCC tumors is not possible. 13 Transarterial chemoembolization has gained recognition since 2018 for reducing tumor mass and alleviating pain in HCC patients. 14,15 However, its efficacy in eradicating cancer cells, especially in highly vascularized tumors, remains limited. 7,16 Currently, multi-kinase inhibitors and immunotherapy are the primary systemic therapies used in HCC treatment. However, the response rate to monotherapy remains below 20%. 11,17 Although existing treatments offer modest improvement in survival and quality of life, recent advancements have been ma -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology